PF-07284892 in Participants With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2370923
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
创建时间：
2021-03-15
